HOLOGRAPHIC NEXT GENERATION GENOMIC DNA SEQUENCING
Dead / Abandoned — Abandoned — failure to respond (as of 23 Aug 2023)
What this means for you
This application is over — abandoned 10 Aug 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90024830
- Mark type
- Stylized text
- Filed
- 28 Jun 2020
- Abandoned
- 10 Aug 2023
Goods and services
- Class 042 — Scientific and technological services: DNA analysis services for scientific research purposes; DNA analysis services to determine paternity; DNA screening for scientific research purposes; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Genome amplification; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of new technology for others in the field of genetics; Development of new technology for others in the field of genomics; Development of new technology for others in the field of holographic genome sequencing; Development of new technology for others in the field of holographic genome testing; Development of new technology for others in the field of gene splicing; Development of new technology for others in the field of holographic gene splicing; Development of new technology for others in the field of decoding genes; Development of new technology for others in the field of decoding genomes; Development of new technology for others in the field of decoding DNA; Development of new technology for others in the field of holographic genome decoding; Development of new technology for others in the field of holographic genomic decoding; Development of new technology for others in the field of genome decoding holography; Development of new technology for others in the field of genomic DNA sequencing; Development of new technology for others in the field of holographic genomic DNA sequencing; Development of new technology for others in the field of genomic DNA sequencing holography; Drug, alcohol and DNA screening for forensic research purposes; Providing information in the field of plant genetics research resources; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing scientific research information in the field of genetics; Providing scientific research information in the field of genomics; Providing scientific research information in the field of holographic genome sequencing; Providing scientific research information in the field of holographic genome testing; Providing scientific research information in the field of gene splicing; Providing scientific research information in the field of holographic gene splicing; Providing scientific research information in the field of decoding genes; Providing scientific research information in the field of decoding genomes; Providing scientific research information in the field of decoding DNA; Providing scientific research information in the field of holographic genome decoding; Providing scientific research information in the field of holographic genomic decoding; Providing scientific research information in the field of genome decoding holography; Providing scientific research information in the field of genomic DNA sequencing; Providing scientific research information in the field of holographic genomic DNA sequencing; Providing scientific research information in the field of genomic DNA sequencing holography; Scientific research consulting in the field of genetics; Scientific research consulting in the field of genomics; Scientific research consulting in the field of holographic genome sequencing; Scientific research consulting in the field of holographic genome testing; Scientific research consulting in the field of gene splicing; Scientific research consulting in the field of holographic gene splicing; Scientific research consulting in the field of decoding genes; Scientific research consulting in the field of decoding genomes; Scientific research consulting in the field of decoding DNA; Scientific research consulting in the field of holographic genome decoding; Scientific research consulting in the field of holographic genomic decoding; Scientific research consulting in the field of genome decoding holography; Scientific research consulting in the field of genomic DNA sequencing; Scientific research consulting in the field of holographic genomic DNA sequencing; Scientific research consulting in the field of genomic DNA sequencing holography; Scientific research in the field of genetics and genetic engineering; Scientific research in the field of genetics; Scientific research in the field of genomics; Scientific research in the field of holographic genome sequencing; Scientific research in the field of holographic genome testing; Scientific research in the field of gene splicing; Scientific research in the field of holographic gene splicing; Scientific research in the field of decoding genes; Scientific research in the field of decoding genomes; Scientific research in the field of decoding DNA; Scientific research in the field of holographic genome decoding; Scientific research in the field of holographic genomic decoding; Scientific research in the field of genome decoding holography; Scientific research in the field of genomic DNA sequencing; Scientific research in the field of holographic genomic DNA sequencing; Scientific research in the field of genomic DNA sequencing holography; Structural and functional analysis of genomes; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy
Owner
- Carl Raymond Amos, Tampa, FL, US
Prior registrations
Prosecution history
- 23 Aug 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 23 Aug 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 23 Aug 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 09 May 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 09 May 2023 — NON-FINAL ACTION E-MAILED
- 09 May 2023 — NON-FINAL ACTION WRITTEN
- 11 Apr 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Apr 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 Apr 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Apr 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 07 Apr 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 07 Apr 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Jan 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Jan 2023 — NON-FINAL ACTION E-MAILED
- 08 Jan 2023 — NON-FINAL ACTION WRITTEN